Genetic polymorghism of CYP2D6 and drug interactions

Abstract

Abstract: As one of major cytochrome P450s, CYP2D6 is responsible for many important drugs' metabolism.The genetic polymorphism of CYP2D6 is the basis of significant individual variability in the metabolism of drugs.Meanwhile, many drugs can influence the activity of CYP2D6 by competitive inhibition or induction, which is easy to cause interaction in coadministration.So we will investigate the relations of genetic polymorphism of CYP2D6 to drug interactions from such aspects as phenotype, competitive inhibition of substrates, induction or inhibition of CYP2D6.

Key words: CYP2D6, genetic polymorphism, drug interactions, inhibition, induction

CLC Number:

R969.2

LI Qin, WANG Rui. Genetic polymorghism of CYP2D6 and drug interactions[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2006, 11(4): 369-374.

References

1 孙忠实, 朱珠.药物代谢性相互作用研究进展[J].医药世界, 2004;8:60-1
2 付良青, 吴德政.细胞色素P4502D6 的研究进展[J].中国临床药理学杂志, 2000;16:453-7
3 http://www.imm.ki.se/CYPallele/cyp2d6.htm
4 Vandel P, Haffen E, Nezelof S.Clomipramine, fluoxetine and CYP2D6 metabolic capacity in depressed patients[J].Hum Psychopharmacol, 2004;19:293-8
5 Eap CB, Sirot EJ, Baumann P.Therapeutic monitoring of antidepressants in the era of pharmacogenetics studies[J].Ther Drug Monit, 2004;26:152-5
6 Brosen K.Some aspects of genetic polymorphism in the biotransformation of antidepressants[J].Therapie, 2004;59:5-12
7 Eap CB, Bondolfi G, Zullino D, Savary-Cosendai L, Powell-Golay K, Kosel M, et al.Concentrations of the enantiomers of fluoxetine and norfluoxetine after multiple doses of fluoxetine in cytochrome P4502D6 poor and extensive metabolizers[J].J Clin Psychopharmacol, 2001;21:330-4
8 Vandel S, Bertschy G, Baumann P, Bouquet S, Bonin B, Francois T, et al.Fluvoxamine and fluoxetine:interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients[J].Pharmacol Res, 1995;31:347-53
9 Yoon YR, Cha IJ, Shon JH, Kim KA, Cha YN, Jang IJ, et al. Relationship of paroxetine disposition to metoprolol metabolic ratio and CYP2D6 ＊ 10 genotype of Korean subjects[J].Clin Pharmacol Ther, 2000;67:567-76
10 Kari L, Steven DB, Harry B, Juha R, Jutta H, Harry S, et al. Effect of the novel anxiolytic drug deramciclane on cytochrome P450 2D6 activity as measured by desipramine pharmacokinetics [J].Eur J Clin Pharmacol, 2004;59:893-8
11 Brosen K, Hansen JG, Nielsen KK, Sindrup SH, Gram LF.Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine[J].Eur J Clin Pharmacol, 1993;44:349-55
12 Tsuyoshi F, Isamu Y, Yuko N, Qian Z, Masako O, Kanji T, et al.Effect of CYP2D6＊10 genotype on venlafaxine pharmacokinetics in healthy adult volunteers[J].Br J Clin Pharmacol, 1999;47:450-3
13 Albers LJ, Reist C, Vu RL.Effect of venlafaxine on imipramine metabolism[J].Psychiatry Res, 2000;96:235-43
14 Taguchi M, Nozawa T, Kameyama T, Inoue H, Takesono C, Mizukami A, et al.Effect of CYP2D6 ＊ 10 on pharmacokinetic variability of routinely administered metoprolol in middle-aged and elderly Japanese patients[J].Eur J Clin Pharmacol, 2003; 59:385-8
15 Chen B, Cai WM.Influence of CYP2D6 ＊ 10B genotype on pharmacokinetics of propafenone enantiomers in Chinese subjects [J].Acta Pharmacol Sin, 2003;24:1277-80
16 杨露芳, 诸骏仁.普罗帕酮的药物相互作用[J].中华心血管病杂志, 1997;25:480-2
17 Giessmann T, Modess C, Hecker U, Zschiesche M, Dazert P, Kunert-Keil C, et al.CYP2D6 genotype and induction of intestinal drug transporters by rifampin predict presystemic clearance of carvedilol in healthy subjects[J].Clin Pharmacol Ther, 2004; 75:213-22
18 Graff DW, Williamson KM, Pieper JA, Carson SW, Adams KF Jr, Cascio WE, et al.Effect of fluoxetine on carvedilol pharmacokinetics, CYP2D6 activity, and autonomic balance in heart failure patients[J].J Clin Pharmacol, 2001;41:97-106
19 Grozinger M, Dragicevic A, Hiemke C, Shams M, Muller MJ, Hartter S.Melperone is an inhibitor of the CYP2D6 catalyzed Odemethylation of venlafaxine[J].Pharmacopsychiatry, 2003;36: 3-6
20 Spina E, Avenoso A, Scordo MG, Ancione M,Madia A, Gatti G, et al.Inhibition of Risperidone Metabolism by Fluoxetine in PatientsWith Schizophrenia:A Clinically Relevant Pharmacokinetic Drug Interaction[J].J Clin Psychopharmacol, 2002;22:419-23
21 Taylor D.Pharmacokinetic interactions involving clozapine[J]. Br J Psychiatry, 1997;171:109-12
22 Ereshefsky L, Riesenman C, Lam YW.Antidepressant drug interactions and the cytochrome P450 system.The role of cytochrome P450 2D6[J].Clin Pharmacokinet, 1995;29:10-8
23 Alfaro CL, Lam YW, Simpson J.CYP2D6 inhibition by fluoxetine, paroxetine, sertraline, and venlafaxine in a crossover study:intraindividual variability and plasma concentration correlations[J].J Clin Pharmacol, 2000;40:58-66
24 Hamelin BA, Bouayad A,Methot J, Jobin J, Desgagnes P, Poirier P, et al.Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity[J].Clin Pharmacol Ther, 2000;67:466-77
25 Etienne LM, Marie YB, Bettina AH.Diphenhydramine alters the disposition of venlafaxine through inhibition of CYP2D6 activity in humans[J].J Clin Psychopharmacol, 2001;21:175-84
26 Eap CB, Lessard E, Baumann P, Brawand-Amey M, Yessine MA, Hara GO, et al.Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans[J].Pharmacogenetics, 2003; 13:39-47
27 Hsu A,Granneman GR, Bertz RJ.Ritonavir.Clinical pharmacokinetics and interactions with other anti-HIV agents[J].Clin Pharmacokinet, 1998;35:275-91
28 Kelly DV, Beique LC, Bowmer MI.Extrapyramidal symptoms with ritonavir/indinavir plus risperidone[J].Ann Pharmacother, 2002;36:827-30
29 Jover F, Cuadrado JM, Andreu L, Merino J.Reversible coma caused by risperidone-ritonavir interaction[J].Clin Neuropharmacol, 2002;25:251-3
30 Cvetkovic RS, Goa KL.Lopinavir/ritonavir:a review of its use in the management of HIV infection[J].Drugs, 2003;63:769-802
31 王娜, 刘会臣, 候艳宁.细胞色素P4502D6 与药物代谢 [J].中国临床药理学杂志, 2001;17:308-12
32 Spina E, Avenoso A, Campo GM.Phenobarbital induces the 2-hydroxylation of desipramine[J].Ther Drug Monit, 1996;18:60-4

[1]	HE Xueru, LI Ying, MA Yinling, FU Yuhao, XUN Xuejiao, DONG Zhanjun. Pharmacokinetic interaction study between sorafenib and dapagliflozin in rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 498-507.
[2]	ZHANG Mingkang, MA Yanrong, JIN Yongwen, ZHOU Yan, CUI Ruirui, WU Xin'an. Advances in clinical research on drug-induced acute interstitial nephritis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 419-428.
[3]	LIU Lu, SHI Yufei, HE Qingfeng, XU Fengyan, WANG Kun, CAI Weimin, XIANG Xiaoqiang. Application of population modeling analysis to evaluate the impact of gene polymorphism on drug PK/PD [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1275-1282.
[4]	HE Xueru, FU Yuhao, XUN Xuejiao, CUI Yanjun, DONG Zhanjun. Advances in uridine diphosphate glucuronosyltransferase-mediated drug interactions with tyrosine kinase inhibitors [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 936-945.
[5]	LIU Lu, CHEN Xiaoyan. Current status of clinical drug-drug interactions research of innovative small molecule drugs in China [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(8): 863-875.
[6]	SUN Bo, FU Shujun, CHEN Guiliang, LI Li. Applications of Drug Interaction Study in New Drug Development and Regulartory Decision-making [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(10): 1095-1102.
[7]	LIN Rongfang, ZHENG Weiwei, LIU Yiwei, LIN Cuihong, WANG Changlian, HUANG Pinfang. Correlation of infliximab related genetic polymorphism, serum trough concentration and efficacy in patients with Crohn's disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(9): 1000-1006.
[8]	PENG Jing, LIU Jun, XU Huifang, LI Yueran, JIANG Jia, WANG Sheng, ZHOU Dexi, ZHU Yanhong, YANG Kui, LUAN Jiajie. Correlation study between cytochrome P4502C19 gene polymorphism or metabolic type and ADP induced-platelet aggregation inhibition and clopidogrel resistance [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(7): 746-751.
[9]	TANG Mufei, SHEN Yunzhu, ZHANG Baoguo. Influence of CYP2D6 gene polymorphism on the effect of tropisetron in preventing chemotherapy induced nausea and vomiting [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(7): 817-822.
[10]	LI Ling, ZHAO Huijia, CHEN Binyao, LIU Xiaohong, SUN Gongpeng, HAO Zhuowen, FAN Zhipeng, YUE Jiang, WU Jianguo, YE Qifa. Relevance of CYP2R1 genetic polymorphism and individual therapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(9): 1053-1059.
[11]	WANG Ente, ZHANG Xiaodan, ZHOU Shuang, ZHAO Xia, ZHOU Ying, CUI Yimin. Effects of genetic polymorphisms on metabolic kinetics, pharmacodynamics and adverse reactions of amitriptyline [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(2): 235-240.
[12]	ZHANG Jingxian, CHEN Tao, ZHANG Xiangqi, SHI Meizhi, CHEN Junjun, ZHANG Kezhi, YANG Jiao, GUO Cheng, WANG Laiyou, HAN Yonglong. Inhibition effects of Danhong injection on three transporters in human primary hepatocytes in vitro [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(4): 389-394.
[13]	ZHAO Wenbin,WANG Xueping,CHEN Xiangjun. Effects of prostaglandin E2 assisted balloon application on vaginal delivery, cervical ripening and induction of labor in term vaginal delivery [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(2): 189-193.
[14]	CHEN Binyao, LI Ling, ZHAO Huijia, LIU Xiaohong, QI Zhenhua, SUN Gongpeng, HAO Zhuowen, FAN Zhipeng, DONG Li, YUE Jiang, YE Qifa. Relevance of CYP1B1 genetic polymorphism and individual therapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(11): 1309-1316.
[15]	HUANG Qiong, DU Jie, CHENG Shuqiao, GONG Zhicheng. Progress of proton pump inhibitors using in cancer patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(10): 1179-1187.